A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer.

Trial Profile

A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2016

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 01 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
    • 03 Mar 2014 Planned End Date changed from 1 Jan 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top